224 related articles for article (PubMed ID: 38673931)
1. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.
Feier CVI; Vonica RC; Faur AM; Streinu DR; Muntean C
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673931
[TBL] [Abstract][Full Text] [Related]
2. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
4. Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA; Crannage EF; Kerwin LC; Guyton JE
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Li J; He K; Ge J; Li C; Jing Z
Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
[TBL] [Abstract][Full Text] [Related]
6. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
7. Practical guidance for use of oral semaglutide in primary care: a narrative review.
Morales J; Shubrook JH; Skolnik N
Postgrad Med; 2020 Nov; 132(8):687-696. PubMed ID: 32643514
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.
Li X; Qie S; Wang X; Zheng Y; Liu Y; Liu G
Endocrine; 2018 Dec; 62(3):535-545. PubMed ID: 30101378
[TBL] [Abstract][Full Text] [Related]
9. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
Andersen A; Knop FK; Vilsbøll T
Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
Drab SR
Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
[TBL] [Abstract][Full Text] [Related]
11. Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
Semenya AM; Wilson SA
Am Fam Physician; 2020 Nov; 102(10):627-628. PubMed ID: 33179892
[No Abstract] [Full Text] [Related]
12. Safety of injectable semaglutide for type 2 diabetes.
Peter R; Bain SC
Expert Opin Drug Saf; 2020 Jul; 19(7):785-798. PubMed ID: 32428416
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
15. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
Iqbal J; Wu HX; Hu N; Zhou YH; Li L; Xiao F; Wang T; Jiang HL; Xu SN; Huang BL; Zhou HD
Obes Rev; 2022 Jun; 23(6):e13435. PubMed ID: 35194917
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6.
Nauck MA; Quast DR
Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484
[TBL] [Abstract][Full Text] [Related]
19. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial.
Kaku K; Yamada Y; Watada H; Abiko A; Nishida T; Zacho J; Kiyosue A
Diabetes Obes Metab; 2018 May; 20(5):1202-1212. PubMed ID: 29322610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
